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Abstract
We report on the tenth bi-annual Great Lakes Glial meeting, held in Traverse City, Michigan, USA, September 27–29
2015. The GLG meeting is a small conference that focuses on current research in glial cell biology. The array of
functions that glial cells (astrocytes, microglia, oligodendrocytes, Schwann cells) play in health and disease is
constantly increasing. Despite this diversity, GLG meetings bring together scientists with common interests, leading
to a better understanding of these cells. This year’s meeting included two keynote speakers who presented talks on
the regulation of CNS myelination and the consequences of stress on Schwann cell biology. Twenty-two other talks
were presented along with two poster sessions. Sessions covered recent findings in the areas of microglial and
astrocyte activation; age-dependent changes to glial cells, Schwann cell development and pathology, and the role
of stem cells in glioma and neural regeneration.
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Schwann cells in health and disease
The contributions of Schwann cells (SC) to peripheral
neuropathy were covered in several talks. Larry Wrabetz
(University of Buffalo, Buffalo, NY) started off the meet-
ing with a brief review of possible causes of hereditary
peripheral neuropathies, citing Charcot-Marie-Tooth 1B
(CMT-1B) disease as an example due to a deletion in the
myelin P0 protein. Surprisingly, the mechanism by
which this mutation induces pathology is not directly re-
lated to its role in myelination, but instead to induction
of the unfolded protein response (UPR). On that basis,
Wrabetz carried out studies in mice harboring the P0
deletion using Sephin1, a new holophosphatase inhibitor.
Sephin1 selectively binds to and inhibits the stress-
induced phosphatase PPP1R15A, reduced the conse-
quences of the UPR, and prevented dysmyelination and
motor function pathology. The findings have a poten-
tially large impact, since endoplasmic reticulum stress,
the UPR, and pathological proteostasis have been docu-
mented not only in patients with CMT, but also in neu-
rodegenerative diseases such as Alzheimer’s Disease.
This suggests that pathological proteostasis may repre-
sent a common therapeutic target for a variety of neuro-
degenerative diseases.
Jun Li (Vanderbilt University, Nashville, TN) organized
a session to discuss molecular signals underlying
Schwann cell (SC) maturation and myelination activities.
One class of molecules gaining increased interest is
extracellular matrix (ECM) molecules. Recent studies
presented by Kelly Monk (Washington University, St
Louis, MO), show that a class of G-protein coupled
receptors termed adhesion GPCRs (aGPCRs), are major
regulators of SC development and myelination. The
aGPCRs are 7-transmembrane domain-containing pro-
teins with long extracellular N-termini. Within the
terminus region are conserved domains that allow in-
teractions with other proteins, as well as a GPCR
auto-proteolysis-inducing (GAIN) domain and a GPCR
proteolytic site (GPS). Upon activation, cleavage occurs
leading to release of the N-terminus and induction of
intracellular signaling pathways. Monk went on to show
that in zebrafish, the aGPCR GPR126 is critical for radial
sorting of axons and myelination. Understanding the
activities and regulation of GPR126 (and other related
aGPCRs) may therefore provide a means to stimulate
remyelination following injury or during disease.
Proteolytic cleavage appears to play many important
roles in SC maturation and function. Riqiang Yan
(Cleveland Clinic, Cleveland, Ohio) presented data
showing that the BACE1 (B-site APP cleaving enzyme 1,
which has important roles in the non-amyloidogenic
processing of APP) is needed during development for
* Correspondence: dlfeins@uic.edu
1Department Anesthesiology, University of Illinois-Chicago, Chicago, IL 60612,
USA
2Jesse Brown VA Medical Center, Chicago, IL 60612, USA
Full list of author information is available at the end of the article
© 2016 Feinstein and Skoff. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Feinstein and Skoff Journal of Neuroinflammation  (2016) 13:69 
DOI 10.1186/s12974-016-0534-6
proper myelination, and in adults for remyelination of
injured sciatic nerves. However, the targets of BACE1
within SCs are not clear. Yan presented data indicating
that cleavage of neuregulin type 1 (Nrg1) within SC is
critical to the ability of the cells to remyelinate injured
nerves. Considering what is already known regarding
BACE1 in the context of AD, these findings open up
new possibilities for increasing peripheral remyelination
by selectively activating BACE1 in SCs.
Inherited mutations in the PMP22 gene are associated
with the most common types of inherited neuropathies,
including hereditary neuropathy with liability to pressure
palsies (HNPP) caused by PMP22 deficiency. Interest-
ingly, PMP22 deficiency causes impaired propagation of
nerve action potentials in the absence of demyelination,
suggesting other functions for PMP22. Jun Li showed
using Pmp22+/− mice as a model of HNPP the presence
of disruptions in multiple types of cell junction com-
plexes in peripheral nerve, associated with increased
myelin permeability and impaired action potential
propagation. Since PMP22 is known to interact with
immunoglobulin domain-containing proteins such as
junctional adhesion molecule-C (JAM-C) and myelin-
associated glycoprotein (MAG), he described studies
to show that deletion of Jam-c or Mag recapitulates
the neuropathology observed in HNPP. These studies
reveal a novel mechanism by which PMP22 deficiency
can affect nerve conduction which does not involve
myelin removal but instead disruption of myelin junctions.
Novel regulators of microglial function
The importance of microglial cells in virtually all types
of neurological conditions and diseases is now well-
accepted, requiring an understanding of their protective
roles as well as their pathological roles. Jyoti Watters
(University of Wisconsin, Madison, WI) organized a ses-
sion addressing studies to determine how microglial
functions are regulated at the epigenetic level, to identify
similarities of actions in diverse disorders (migraine and
multiple sclerosis), and to understand how aging alters
their functions.
Epigenetic modifications occur following various stim-
uli, including inflammatory activation. Watters described
studies of epigenetic modifications in microglia during
periods of chronic neuroinflammation induced by repeti-
tive intermittent hypoxia, a model of sleep apnea. It was
known prior to these studies that in this model, the
microglial phenotype shifts to a pro-inflammatory state
(M1) early during pathology, and then to a reparative or
neurosupportive state (M2) at later times. She showed
that in this model, the activities of the Jumonji family of
histone demethylases were necessary for the M1 pheno-
type, while expression of miRNAs appeared important
for dampening the inflammatory response and enabling
an M2 phenotype. Surprisingly, the activity of toll-like
receptor 4 (TLR4) was necessary for transition to both
the M1 and M2 phenotypes, pointing to a dual role for
this key molecule. It is suggested that similar regulatory
mechanisms may be involved in microglial adaptation to
situations of chronic neuroinflammation in other models
of neural injury and degeneration as well.
Richard Kraig (University of Chicago, Chicago, IL)
presented work which highlighted similarities between
migraine and multiple sclerosis (MS), two seemingly
disparate diseases. Migraine occurs two to three times
more frequently in MS patients, and patients suffering
from migraine with aura display white matter abnor-
malities. He presented in vitro and in vivo data show-
ing that spreading depression (SD), the underlying
cause of migraine with aura, produced abnormalities
in myelin mediated by immune cell activation and
IFNγ production, similar to MS. Importantly, IFNγ
appears to have a dual role in these diseases, since
environmental enrichment (EE), intranasal IFNγ deliv-
ery in animals, or phasic application of IFNγ in slice
cultures reduced oxidative stress, increased myelin
proteins, and increased the threshold for SD. How
these protective actions of IFNγ occur is unclear, but
Kraig posited that exosomes released following EE or
from IFNγ-stimulated microglia contain miRNAs that
reduce oxidative stress and promote myelination. The
work suggests that IFNγ, in the absence of other factors
that normally trigger immune activation and exacerbates
disease, can instead promote the production of exosomes
that enhance brain health.
The role of astrocytes in health and disease
Accumulating evidence indicates that astrocytes and
neuroinflammation can either be detrimental or benefi-
cial in neurological diseases. Sandra Hewett (Syracuse
University, Syracuse, NY) organized a session to discuss
the pros and cons of astrocyte immunomodulatory
signaling in CNS disease. The role of astrocyte TGFβ
signaling in toxoplasmic encephalitis―an inflammatory
disease of the CNS caused by infection with Toxoplasma
gondii―was explored by Marion Buckwalter (Stanford
University, Stanford, CA). Using a mouse model of in-
fection, Buckwalter showed that, despite no differences
in Toxoplasma burden, mice with impaired astrocytic
TGFβ signaling exhibited twofold greater neuronal dam-
age and increased myeloid cell activation and lympho-
cyte infiltration into the CNS compared to controls. The
data suggest that astrocyte TGFβ limits peripheral im-
mune infiltration and injury after infection. As TGFβ
upregulation occurs in other acute brain injuries and
diseases, TGFβ signaling may present a universal
pathway by which astrocytes limit neuroinflammation
and injury.
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M. Kerry O’Banion (University of Rochester, Rochester,
NY) demonstrated previously that sustained astrocytic
IL-1β expression reduced amyloid beta (Aβ) plaque size
and frequency in a mouse model of AD. O’Banion now
reported that persistent expression of IL-1β in brains of
those mice led to an IL-4-dependent alternative activa-
tion of microglia that played an essential role in Aβ
clearance. By contrast, using an antibody to block IL-4
signaling, he showed a reduction in arginase-1-positive
microglia in IL-1b-expressing mice, coincident with
reduced Aβ clearance. These data suggest that
neuroinflammation-dependent changes in microglial
phenotype impact Aβ plaque load, and potentially
other neuropathologies.
Continuing the study of IL-1β, Hewett described its
paradoxical role in acute CNS injury and protection.
Previous work from her group demonstrated that injury
facilitated by IL-1β upregulation in stroke was likely me-
diated by enhancement in astrocyte system Xc
− activity.
However, she presented data detailing that this enhance-
ment could increase also astrocyte glutathione (GSH)
production, thereby reducing susceptibility to oxidant
injury. IL-1β reduced production of reactive oxygen
species in astrocytes generated by exposure to tert-
butyl hydroperoxide, and that toxicity (or that due to
iron) was attenuated by IL-1β. Protection was re-
versed by concomitant exposure to L-buthionine-S,R-
sulfoximine, which prevented the IL-1β-mediated rise
in GSH production. Given these results, Hewett pos-
ited that the increase in IL-1β expression after stroke
insult or injury may be part of a protective response
which ultimately goes awry.
Finally, John Bethea (Drexel University, Philadelphia,
PA) described the role of astroglial NF-κB signaling in
models of MS. Extending earlier findings that inactiva-
tion of astroglial NF-κB in vivo improved functional out-
come in experimental autoimmune encephalomyelitis
(EAE), Bethea presented evidence showing that the key
element driving recovery was reduced immune cell infil-
tration into the CNS at the chronic phase of disease, oc-
curring independently from alterations in blood brain
barrier permeability. Further, he presented results dem-
onstrating a reduction in the number and activation
state of resident microglia, and in the Th1 and Th17
profile of infiltrating T-cells during acute disease. Col-
lectively, these data underscore that astrocytes, either
directly or indirectly, play a critical function in regulat-
ing CNS inflammation that follows EAE, hence driving
disease progression and severity.
The aging glial cell
It was clear from several presentations that microglial
function is regulated by environmentally induced epi-
genetic changes, and to production of exosomes which
contain miRNAs, another form of epigenetic reprogram-
ming. Similar events occur in most, if not all glial cell
types. Patrizia Casaccia (Icahn School of Medicine at
Mount Sinai, New York, NY) described studies to define
changes in the “epigenetic landscape” of oligodendrocytes
during aging. It was already known that oligodendrocyte
maturation is accompanied by specific histone modifica-
tions including decreased acetylation and increased tri-
methylation of histone H3-K9 and K27. She showed that
aging reverses those changes, and is associated with re-
expression of transcriptional inhibitors as well as ineffi-
cient myelin repair in older mice. She then presented new
data showing that molecules which block interactions of
acetylated lysines with bromodomain-specific proteins
allow oligodendrocytes to overcome the blocks induced by
hyperacetylation. The potential of epigenome modulators
therefore could include reversal of age-related epigenetic
dysfunction in oligodendrocytes.
The ways that microglial functions change with age is
critical to understanding and developing interventions
for neurodegenerative diseases for which age is the
greatest risk factor. Anne Boullerne (University of Illinois,
Chicago, IL) organized a session to address the conse-
quences of aging on glial cell function. Diana Norden
(Ohio State University, Columbus, OH) described how
microglial inflammatory activities shift during aging to
become “primed” or more highly pro-inflammatory.
The aged microglia have an amplified and prolonged
pro-inflammatory response that results from impair-
ments in key anti-inflammatory systems coming from
astrocytes. She reported that aged astrocytes have reduc-
tions in IL-10R1 expression, which causes the astrocytes
to host aberrant responses to IL-10. This results in
reduced TGFβ signaling to the microglia, allowing for
increased inflammatory responses. Thus, understanding
how aging changes normal astrocyte-microglia communi-
cation is necessary to identify novel targets for therapeutic
interventions.
Wolfgang Streit (University of Florida, Gainesville, FL)
presented images from human autopsy samples of con-
trols and AD patients to understand the changes that
occur to microglia cytoplasmic structure as a result of
cell senescence. Streit hypothesized that Alzheimer-type
neurofibrillary degeneration (tau pathology) occurs as a
consequence of an aging-related decline in microglial
ability to support neurons. He showed that the appear-
ance of tau-positive structures (neurofibrillary tangles,
neuropil threads, and senile plaques) in the entorhinal
cortex and surrounding temporal gyri is preceded and
accompanied by widespread microglial dystrophy. The
extent of microglial degeneration correlates positively
with development of neurodegeneration in both AD and
Down syndrome, supporting the hypothesis of microglial
dysfunction. At the same time, he was unable to detect
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the presence of activated microglia in the human tem-
poral cortex, providing evidence against the longstand-
ing idea that neuronal degeneration is a result of overly
activated, out-of-control microglia. Instead, he believes
that the brain’s innate immune system is subject to an
aging-related decline in function due to the senescent
deterioration of microglia. The implications for potential
therapeutic approaches are profound: instead of trying
to suppress microglia with anti-inflammatory drugs to
prevent neurodegeneration, it may be more effective to
develop agents that can stimulate microglial activity.
The effects of aging on glial cells can be further influ-
enced by gender; which could help account for gender
differences in the incidence of neurological conditions
and disease such as MS, AD, and stroke. Farida Sohrabji
(Texas A&M Health Science Center, Bryan, TX) pre-
sented data regarding changes in astrocytes that occur
during aging and during recovery from ischemic stroke.
Not only do women suffer more severe stroke than men,
but this phenomenon is replicated in animal studies
where aging females have more extensive brain loss
compared to younger females. Sohrabji showed that, in
comparison to young females, astrocytes from aged
female rats secrete less IGF-1 (which shows beneficial
effects in stroke), have reduced capacity for glutamate
clearance, and paradoxically synthesize higher levels of
inflammatory cytokines. In co-cultures, aging astrocytes
showed a greater propensity to recruit monocytes across
a Transwell system, indicating a potential for a more
severe inflammatory response. Sohrabji showed that the
age-dependent changes in astrocytes involve epigenetic
modifications, with astrocytes from the ischemic cortex
of adult female rats having more histone H3 lysine 4 tri-
methylation than middle-aged female astrocytes. Collect-
ively, these studies show that the functional capacity of
aging astrocytes is impaired and may be associated with
the greater stroke impairment seen in aging females.
Is there a way to combat the consequences of aging in
glial cells? Carmela Abraham (Boston University School
of Medicine, Boston, MA) discussed the roles that the
anti-aging protein Klotho has in the early differentiation
of oligodendrocytes and their capacity for remyelination
in the adult CNS. Klotho, which is significantly down-
regulated in the aged brain, was discovered to play a role
in aging when Klotho-deficient mice were found to
exhibit signs of aging and premature death. Abraham
showed that Klotho-knockout mice suffer from severe
hypomyelination. Furthermore, the addition of Klotho to
oligodendrocyte progenitor cells induced their maturation
to myelin-producing oligodendrocytes. Most interestingly,
Klotho-overexpressing mice show better cognition in a
number of behavioral tasks. Finally, when demyelination
was induced by cuprizone, the number of remyelinated
axons was twice as high in Klotho overexpressing mice
compared to controls. These findings raise the prospect
that methods to increase Klotho, or provide small molecu-
lar weight mimetics, could be used to improve remyelina-
tion as well as cognitive deficits in neurological disorders
and diseases.
The Janus face of stem cells: roles in
neuroregeneration and cancer
Given the age and disease-related changes in glial cells
that likely worsen neuropathology, one must consider
methods to replace or correct those deficiencies. To-
wards those goals, Margot Mayer Proschel (University of
Rochester, Rochester, NY) organized a session to discuss
the potential use of stem cells as therapeutics, and how
knowledge of stem cell biology can inform us of mecha-
nisms that underlie diseases.
The potential of astrocyte-based therapies for CNS
repair was presented by Chris Proschel (University of
Rochester, Rochester, NY). He shared data that demon-
strated the ability of astrocyte transplants to promote
motor recovery in rat models of both traumatic spinal
cord injury and in a neurotoxic model of PD. His work
underscored the versatility of astrocytes to restore
neuronal function of the host even after delayed
transplantation. Importantly, the therapeutic benefits
were only observed with a specific subpopulation of
astrocytes generated in vitro by directed differentiation
from stage-specific precursor populations using bone
morphogenetic protein-4. Proschel’s work demonstrated
that the therapeutic potential was associated with distinct
expression patterns of growth factors, extracellular matrix
proteins, and synaptogenic factors, thus highlighting the
importance of using the appropriate precursor population
and differentiation method to obtain therapeutically com-
petent astrocytes.
Mark Noble (University of Rochester, Rochester, NY)
extended the discussion of therapeutic strategies and
presented an integration of progenitor cell biology, redox
biology, signaling pathway analysis, and drug discovery
that is providing new therapeutic approaches for glio-
blastoma (GBM) treatment. Analyses of glial progenitor
cell function had previously revealed that small changes
in intracellular redox state are critical in modulating sur-
vival and differentiation. The central mechanism control-
ling these outcomes appears to be the redox/Fyn/c-Cbl
pathway. Activation of this pathway promotes lysosomal
degradation of important receptor tyrosine kinases in-
cluding PDGRα and EGFR, with subsequent suppres-
sion of downstream signaling. c-Cbl can be inhibited
upon complex formation with a guanine nucleotide
exchange factor called Cool-1/ß-pix. Noble reported
that c-Cbl activation may be essential for GBM
tumorigenesis, since Cool-1/ß-pix knockdown elimi-
nated the ability of GBM cells to generate tumors,
Feinstein and Skoff Journal of Neuroinflammation  (2016) 13:69 Page 4 of 5
increased their sensitivity to chemotherapeutic agents,
and restored the ability to activate c-Cbl. Noble
highlighted the tumor selective nature of this pathway
as Cool-1 knockdown in primary glial progenitor cells
did not have these effects. Based on these findings,
Nobel reported discovery of several drugs, previously
approved for other purposes, that restore c-Cbl function
in GBM cells. These drugs confer sensitivity to standard
of care treatments for GBM both in vitro and in vivo,
and provide exciting opportunities for moving rapidly
to clinical trials.
Biplab Dasgupta (University of Cincinnati, Cincinnati,
OH) further expanded upon the role of metabolic
changes in GBMs, and discussed new studies focusing
on the liver kinase B1 (LKB1):adenosine monophosphate
kinase (AMPK) pathway which regulates cellular meta-
bolic processes. Dasgupta found several AMPK subunits
and active AMPK overexpressed in human GBMs and in
mouse models of high-grade glioma. Silencing AMPK
reduced the viability of patient-derived primary GBM cells
in vitro and suppressed tumor growth in vivo. His work
suggests that in the context of GBMs, AMPK positively
regulates the transcription program of both glycolysis and
mitochondrial respiration and thus influences the global
bioenergetic program of GBM.
The role of LKB1 in CNS was further discussed by
David Braun (University of Illinois, Chicago, IL). He
presented data showing that loss of LKB1 from primary
cortical astrocytes was associated with an increase in
proliferation, a loss of contact inhibition, induction of
anchorage-independent proliferation, and enhanced
migratory capability; all properties similar to those
observed in GBMs. He went on to show that the
LKB1 null astrocytes expressed known markers of
pluripotency including Sox2, Oct4, and Nanog, sug-
gesting that lack of LKB1 caused de-differentiation of
the astrocytes towards a more primitive cell type. He
then showed tantalizing data that these “stem-like”
cells could be induced to differentiate into oligoden-
drocytes or neurons in vitro depending upon growth
conditions. Braun suggested that inhibition of LKB1
activity may represent a novel way of reprogramming
astrocytes, which could help improve efficiency of
reprogramming of other cell types, or of developing
new models of GBMs.
Conclusions
Robert Skoff (Wayne State University, Detroit, MI) sum-
marized the presentations and highlighted the contribu-
tions of the younger investigators who constituted
roughly 50 % of the attendees. As discoveries in glial cell
biology continue to emerge, all look forward to the next
meeting to take place in 2017.
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